A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland.
We recently have conducted a cross-sectional survey to determine the prescribing practices of rheumatologists and a random sample of general practitioners in New South Wales and Queensland. While in general there was agreement as to the preferred management of gout, several important differences were noted between the two groups of doctors. In particular, general practitioners were more liberal than were rheumatologists in their use of allopurinol. However, they were less likely to cover the introduction of allopurinol with anti-inflammatory agents, to titrate the dose against the serum uric acid level or to adjust the dose according to the serum creatinine level. A small number of doctors continued to use urate-lowering drugs as a routine in the treatment of entirely asymptomatic hyperuricaemia. The data indicate a continuing need to disseminate information regarding the preferred management of hyperuricaemic states.
Bellamy
N
N
University of Western Ontario, Victoria Hospital, London, Canada.
Brooks
P M
PM
Emmerson
B T
BT
Gilbert
J R
JR
Campbell
J
J
McCredie
M
M
D000493:Allopurinol / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D015210:Arthritis, Gouty / Q000188:drug therapy* / Q000378:metabolism; D003078:Colchicine / Q000627:therapeutic use; D004363:Drug Utilization; D005194:Family Practice; D006801:Humans; D009517:New South Wales; D011793:Queensland; D012219:Rheumatology; D014527:Uric Acid / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D014527:Uric Acid; D000493:Allopurinol; D003078:Colchicine